A Long-term Safety Study of Once-daily Travatan

Phase 3CompletedNCT00051168

Alcon Research502 enrolled

Overview

Long term safety study of TRAVATAN in patients with Open-angle glaucoma or ocular hypertension.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

502

Conditions

Glaucoma, Open-angle Ocular Hypertension

Interventions

TravatanDRUG

Travoprost (0.004%) 1 drop each eye once daily

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Adult patients of any race and either sex with chronic angle-closure glaucoma.

Locations (1)

Europe

Fort Worth, Texas, United States

Outcomes

Primary Outcomes

Mean Intraocular Pressure

Mean IOP for the patient's worse eye at baseline was used in the secondary endpoint analysis. 2 consecutive IOP measurements for each eye were taken. If the 2 measurements for the same eye differ by 4 mmHg or less, the average of the measurements would be considered as the mean IOP for that eye. If the 2 measurements for the same eye differ by more than 4 mmHg, then a third measurement was to be taken. All IOP measurements were performed with a Goldmann applanation tonometer.

Time frame: At 5 years.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.